BioSpace News Archive

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2022 financial results and provided a business update.

AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported financial results for the second quarter ended June 30, 2022.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the second quarter of 2022, and associated Company developments.

NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended June 30, 2022.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2022.

Cognition Therapeutics, Inc. announced that Mary Hamby, Ph.D., vice president of research, presented results at the at Alzheimer’s Association International Conference of proteomic analysis of clinical biomarker data from the SPARC study of oral once-daily treatment with CT1812 in mild-to-moderate Alzheimer’s disease.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported financial results for the quarter ended June 30, 2022, and provided a business update.

Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2022 and raised net sales guidance for INGREZZA in 2022.

Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.